LibraGen, a company specialising in the development of new enzymes to improve manufacturing processes in the pharmaceutical and chemical industries, has teamed up with fellow French firm Synkem.
The two firms have entered a non-exclusive agreement to co-market their products and outsourcing services to customers, and will also collaborate on the development of new projects.
LibraGen has developed a platform that allows it to discover new enzymes from metabolic pathways that are not exploited by the industry at present. Synkem , which specialises in supplying active pharmaceutical ingredients (APIs), will contribute its expertise in process research and Good Manufacturing Practice (GMP) production.
"By entering this partnership, LibraGen will gain access to a wider number of customers" for its biocatalysts, said Renaud Nalin, LibraGen 's CEO.